Glax­o­SmithK­line and Vir sub­mit Covid-19 mAb for emer­gency au­tho­riza­tion

As the US con­tin­ues to mon­i­tor the im­pact of vari­ants on au­tho­rized mon­o­clon­al an­ti­bod­ies (mAbs) and shake up which mAbs are dis­trib­uted where, Glax­o­SmithK­line and Vir Biotech­nol­o­gy said Fri­day that they’re seek­ing an emer­gency use au­tho­riza­tion for their own mAb.

The com­pa­nies are sub­mit­ting an ap­pli­ca­tion for their mAb, known as VIR-7831, as a treat­ment for adults and ado­les­cents (12 years and old­er) with mild-to-mod­er­ate Covid-19 who are at risk for pro­gres­sion to hos­pi­tal­iza­tion or death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER